Rett Syndrome
Overview
Plain-Language Overview
Rett Syndrome is a rare genetic disorder that primarily affects the nervous system and leads to severe developmental problems. It mostly occurs in girls and causes a loss of purposeful hand skills and spoken language after a period of normal development. Children with this condition often develop distinctive hand-wringing movements, problems with walking, and slowed growth of the head. The disorder impacts brain function, leading to difficulties with coordination, communication, and sometimes seizures. It is caused by changes in a gene important for brain development, which disrupts normal nerve cell function.
Clinical Definition
Rett Syndrome is a neurodevelopmental disorder caused by mutations in the MECP2 gene located on the X chromosome, which encodes the methyl-CpG-binding protein 2 involved in transcriptional regulation. It predominantly affects females due to its X-linked dominant inheritance pattern and is characterized by a period of apparently normal early development followed by a regression phase with loss of acquired skills. Key clinical features include loss of purposeful hand use, development of stereotypic hand movements, severe cognitive impairment, gait abnormalities, and autonomic dysfunction. The disorder is significant for its progressive neurological decline and is a major cause of intellectual disability in females. Diagnosis is supported by clinical presentation and confirmed by genetic testing for MECP2 mutations.
Inciting Event
Spontaneous de novo mutation in the MECP2 gene during early embryogenesis.
No environmental or infectious triggers are implicated in disease onset.
Latency Period
Initial normal development for 6 to 18 months before symptom onset.
Progressive neurological regression occurs over months to years after initial symptom appearance.
Diagnostic Delay
Early symptoms such as developmental delay and hypotonia are nonspecific and often misattributed to other neurodevelopmental disorders.
Lack of awareness of the characteristic regression and hand stereotypies delays diagnosis.
Misdiagnosis as autism spectrum disorder or cerebral palsy is common.
Genetic testing for MECP2 mutations may not be performed early due to clinical overlap with other conditions.
Clinical Presentation
Signs & Symptoms
Normal early development followed by regression of speech and motor skills between 6-18 months
Loss of purposeful hand use replaced by repetitive stereotypic hand movements
Severe intellectual disability with impaired communication
Seizures occurring in the majority of patients
Autistic features including social withdrawal and impaired eye contact
Breathing irregularities such as hyperventilation, apnea, and breath-holding
History of Present Illness
Normal early development followed by loss of purposeful hand skills and spoken language.
Emergence of hand-wringing stereotypies and repetitive hand movements.
Progressive microcephaly, gait abnormalities, and seizures develop over time.
Periods of apnea, hyperventilation, and autonomic dysfunction are common.
Cognitive impairment and intellectual disability become apparent as disease progresses.
Past Medical History
Typically unremarkable early infancy with normal growth and development until regression.
No prior neurological or metabolic disorders before symptom onset.
No history of perinatal complications or infections contributing to symptoms.
Family History
Usually sporadic cases due to de novo MECP2 mutations with no affected relatives.
Rare familial cases with X-linked dominant inheritance pattern in females.
No consistent association with other inherited neurodevelopmental syndromes.
Physical Exam Findings
Loss of purposeful hand skills with characteristic repetitive hand-wringing movements
Microcephaly developing after initial normal head growth
Gait abnormalities including ataxia and apraxia
Scoliosis and other musculoskeletal deformities
Hypotonia progressing to spasticity
Bruxism and abnormal breathing patterns such as hyperventilation or apnea
Diagnostic Workup
Diagnostic Criteria
Diagnosis is established based on clinical criteria including a period of normal development followed by regression, loss of purposeful hand skills, development of stereotypic hand movements, and impaired gait. Additional supportive features include breathing irregularities, seizures, and growth retardation. Confirmation requires identification of a pathogenic mutation in the MECP2 gene through genetic testing. Neuroimaging and EEG may support but are not diagnostic.
Pathophysiology
Key Mechanisms
Mutations in the MECP2 gene lead to defective methyl-CpG-binding protein 2, disrupting transcriptional regulation in neurons.
Neuronal maturation and synaptic development are impaired due to altered gene expression caused by MECP2 dysfunction.
Loss of synaptic plasticity and abnormal neurotransmitter release contribute to the neurological symptoms.
Microcephaly results from impaired neuronal growth and dendritic arborization.
Dysregulation of glial cell function may exacerbate neurodevelopmental deficits.
| Involvement | Details |
|---|---|
| Organs | Brain is the primary organ affected, with widespread neurodevelopmental deficits causing cognitive and motor impairments. |
Lungs are involved due to recurrent respiratory infections and breathing irregularities. | |
| Tissues | Cortical gray matter shows reduced volume and synaptic density, reflecting neurodevelopmental impairment. |
White matter abnormalities indicate disrupted myelination and connectivity. | |
| Cells | Neurons are primarily affected due to mutations in MECP2, leading to impaired synaptic function and neurodevelopment. |
Glial cells contribute to altered neuronal support and neuroinflammation in Rett syndrome. | |
| Chemical Mediators | Brain-derived neurotrophic factor (BDNF) levels are reduced, impairing neuronal survival and plasticity. |
Glutamate dysregulation contributes to excitotoxicity and neuronal dysfunction. |
Treatments
Pharmacological Treatments
Baclofen
- Mechanism:
Acts as a GABA-B receptor agonist to reduce spasticity and improve motor function.
- Side effects:
Drowsiness
Muscle weakness
Dizziness
- Clinical role:
Adjunctive
Selective serotonin reuptake inhibitors (SSRIs)
- Mechanism:
Increase serotonin levels to help manage anxiety and mood disturbances.
- Side effects:
Gastrointestinal upset
Sexual dysfunction
Insomnia
- Clinical role:
Supportive
Antiepileptic drugs (e.g., valproate, levetiracetam)
- Mechanism:
Stabilize neuronal membranes and reduce seizure activity.
- Side effects:
Sedation
Ataxia
Hepatotoxicity (valproate)
- Clinical role:
First-line
Non-pharmacological Treatments
Physical therapy to improve motor skills and reduce contractures.
Speech therapy to assist with communication difficulties and apraxia.
Occupational therapy to enhance daily living skills and adaptive techniques.
Nutritional support including gastrostomy feeding for swallowing difficulties.
Regular monitoring and management of scoliosis and orthopedic complications.
Prevention
Pharmacological Prevention
Antiepileptic drugs to prevent seizure complications
Beta-blockers or other agents to manage cardiac arrhythmias
Medications for gastrointestinal symptoms such as proton pump inhibitors
Supplementation with vitamin D and calcium to prevent osteopenia
No current pharmacological agents prevent disease onset or progression
Non-pharmacological Prevention
Early developmental intervention programs to maximize functional skills
Regular orthopedic monitoring and bracing to prevent severe scoliosis
Nutritional support including feeding therapy to prevent malnutrition
Respiratory therapy and airway clearance techniques to reduce infections
Genetic counseling for families to inform recurrence risk
Seizure safety education and monitoring
Outcome & Complications
Complications
Recurrent respiratory infections due to impaired airway protection
Severe scoliosis leading to restrictive lung disease
Status epilepticus from uncontrolled seizures
Malnutrition from feeding difficulties
Aspiration pneumonia
Progressive motor disability leading to loss of ambulation
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Rett Syndrome versus Autism Spectrum Disorder (ASD)
Rett Syndrome | Autism Spectrum Disorder (ASD) |
|---|---|
Normal early development followed by regression between 6-18 months with loss of purposeful hand skills | Symptoms typically present before 3 years with persistent social communication deficits and restricted interests |
Period of normal development followed by rapid regression and subsequent stabilization or partial recovery | Chronic developmental delay without a clear period of regression |
Pathogenic mutations in MECP2 gene detected in most cases | No specific genetic mutation identified |
Rett Syndrome versus Childhood Disintegrative Disorder (CDD)
Rett Syndrome | Childhood Disintegrative Disorder (CDD) |
|---|---|
Regression occurs between 6-18 months after normal early development | Regression occurs after 2 years of apparently normal development |
Loss primarily of purposeful hand skills and spoken language with characteristic hand-wringing | Marked loss of multiple skills including language, social, and motor after 2 years |
Mutations in MECP2 gene confirm diagnosis | No known genetic mutation associated |
Rett Syndrome versus Angelman Syndrome
Rett Syndrome | Angelman Syndrome |
|---|---|
Mutation in MECP2 gene on X chromosome | Deletion or mutation of maternal 15q11-q13 region detected |
Normal early development followed by regression and loss of hand skills | Severe developmental delay with ataxia, frequent laughter, and seizures from infancy |
Characteristic hand-wringing movements and autistic features | Frequent smiling and laughter, ataxic gait, and microcephaly |
Rett Syndrome versus Mitochondrial Encephalopathy
Rett Syndrome | Mitochondrial Encephalopathy |
|---|---|
Regression after normal development with relatively stable chronic phase | Progressive neurological decline with episodic metabolic crises |
Normal metabolic labs, MECP2 mutation present | Elevated lactate and mitochondrial DNA mutations |
Normal or nonspecific MRI findings without stroke-like lesions | Basal ganglia lesions or stroke-like episodes on MRI |
Rett Syndrome versus Severe Cerebral Palsy
Rett Syndrome | Severe Cerebral Palsy |
|---|---|
Normal early development with regression after 6 months | Abnormal motor development evident from birth or early infancy |
Progressive loss of hand skills and communication abilities | Non-progressive motor impairment with spasticity or dystonia |
Brain MRI typically normal or shows nonspecific atrophy | Brain MRI shows periventricular leukomalacia or other static lesions |